Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 108Ovarian Neoplasms 64Neoplasms 61Fallopian Tube Neoplasms 40Lung Neoplasms 37Breast Neoplasms 33Neoplasm Metastasis 25Carcinoma, Ovarian Epithelial 25Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 20Esophageal Neoplasms 19Endometrial Neoplasms 19Colorectal Neoplasms 15Advanced Solid Tumors 14Squamous Cell Carcinoma of Head and Neck 13Lymphoma, Large B-Cell, Diffuse 13Unspecified Adult Solid Tumor, Protocol Specific 12Stomach Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Astrocytoma 10Neuroblastoma 9Medulloblastoma 9Head and Neck Neoplasms 9Carcinoma 9Urinary Bladder Neoplasms 8Solid Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

Gemcitabine 13Cisplatin 9Capecitabine 7durvalumab 6pembrolizumab 4tremelimumab 3S 1 (combination) 3Nivolumab 3AZD 6244 3Ramucirumab 2Fluorouracil 2130-nm albumin-bound paclitaxel 2vandetanib 1trifluridine tipiracil drug combination 1trametinib 1tocilizumab 1titanium silicide 1sacituzumab govitecan 1poly ICLC 1futibatinib 1fludarabine 1cemiplimab 1binimetinib 1aflibercept 1Tegafur 1TAS-116 1Psilocybin 1Peptides 1Oxaliplatin 1NUC-1031 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Biliary Tract Neoplasms × Carboplatin × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡